THAR

Tharimmune, Inc. - Common Stock (THAR)

About Tharimmune, Inc. - Common Stock (THAR)

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Details

Daily high

$4.20

Daily low

$4.00

Price at open

$4.16

52 Week High

$9.08

52 Week Low

$0.95

Market cap

155.4M

Dividend yield

0.00%

Volume

1.1M

Avg. volume

1.4M

P/E ratio

-1.01

Tharimmune, Inc. - Common Stock News